RGCC and neoplasm: Indeed, administration of RGCC deficient MDA-MB-231/LM3 cells showed markedly decreased IC50 values of paclitaxel and carboplatin (Fig. 8A) and tumor cell viability (Fig. 8B) in contrast with RGCC wild type cells, suggesting that RGCC deficiency combined with paclitaxel and carboplatin treatment may have benefits for TNBC patients with lung metastasis.